The forkhead transcription factor FOXM1 promotes endocrine resistance and invasiveness in estrogen receptor-positive breast cancer by expansion of stem-like cancer cells

Breast Cancer Research

Volumn 16, Issue 1, 2014, Pages

  Bergamaschi, Anna ^a   Madak Erdogan, Zeynep ^a   Kim, Yu Jin ^b   Choi, Yoon La ^b,c   Lu, Hailing ^a,d   Katzenellenbogen, Benita S ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b Samsung Medical Center   (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

^d HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR ALPHA; FORKHEAD TRANSCRIPTION FACTOR; FORKHEAD TRANSCRIPTION FACTOR FOXM1; MITOGEN ACTIVATED PROTEIN KINASE 1; TAMOXIFEN; UNCLASSIFIED DRUG; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTROGEN RECEPTOR; FOXM1 PROTEIN, HUMAN; PROTEIN BINDING;

ARTICLE; CANCER RECURRENCE; CANCER RESISTANCE; CELL POPULATION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG RECEPTOR BINDING; ENZYME INHIBITION; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIMIT OF QUANTITATION; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; STEM CELL EXPANSION; TREATMENT OUTCOME; TUMOR INVASION; BREAST NEOPLASMS; CANCER STEM CELL; DRUG RESISTANCE; GENE ONTOLOGY; KAPLAN MEIER METHOD; MCF 7 CELL LINE; METABOLISM; MORTALITY; PATHOLOGY; PHYSIOLOGY;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE ONTOLOGY; HUMANS; KAPLAN-MEIER ESTIMATE; MCF-7 CELLS; NEOPLASM INVASIVENESS; NEOPLASTIC STEM CELLS; PROTEIN BINDING; RECEPTORS, ESTROGEN; TAMOXIFEN; TREATMENT OUTCOME;

EID: 84988826372     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/s13058-014-0436-4     Document Type: Article

References (69)

1. Creighton CJ, Massarweh S, Huang S, Tsimelzon A, Hilsenbeck SG, Osborne CK, Shou J, Malorni L, SchiffR: Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts. Cancer Res 2008, 68:7493-7501
2. SchiffR, Massarweh S, Shou J, Osborne CK: Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin Cancer Res 2003, 9:447S-454S
3. Sengupta S, SchiffR, Katzenellenbogen BS: Post-transcriptional regulation of chemokine receptor CXCR4 by estrogen in HER2 overexpressing, estrogen receptor-positive breast cancer cells. Breast Cancer Res Treat 2009, 117:243-251
4. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, SchiffR: Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004, 96:926-935
5. Arpino G, Wiechmann L, Osborne CK, SchiffR: Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev 2008, 29:217-233
6. Creighton CJ, Hilger AM, Murthy S, Rae JM, Chinnaiyan AM, El-Ashry D: Activation of mitogen-activated protein kinase in estrogen receptor a-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor a-negative human breast tumors. Cancer Res 2006, 66:3903-3911
7. Green KA, Carroll JS: Oestrogen-receptor-mediated transcription and the influence of co-factors and chromatin state. Nat Rev Cancer 2007, 7:713-722
8. Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, Weiss H, Rimawi M, SchiffR: Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res 2008, 68:826-833
9. O'Brien CS, Howell SJ, Farnie G, Clarke RB: Resistance to endocrine therapy: Are breast cancer stem cells the culprits? J Mammary Gland Biol Neoplasia 2009, 14:45-54
10. O'Brien CA, Kreso A, Dick JE: Cancer stem cells in solid tumors: an overview. Semin Radiat Oncol 2009, 19:71-77
11. Jordan CT: Cancer stem cells: controversial or just misunderstood? Cell Stem Cell 2009, 4:203-205
12. Bergamaschi A, Frasor J, Borgen K, Stanculescu A, Johnson P, Rowland K, Wiley EL, Katzenellenbogen BS: 14-3-3ζ as a predictor of early time to recurrence and distant metastasis in hormone receptor-positive and-negative breast cancers. Breast Cancer Res Treat 2013, 137:689-696
13. Bergamaschi A, Christensen BL, Katzenellenbogen BS: Reversal of endocrine resistance in breast cancer: interrelationships among 14-3-3ζ, FOXM1, and a gene signature associated with mitosis. Breast Cancer Res 2011, 13:R70
14. Sanders DA, Ross-Innes CS, Beraldi D, Carroll JS, Balasubramanian S: Genome-wide mapping of FOXM1 binding reveals co binding with estrogen receptor a in breast cancer cells. Genome Biol 2013, 14:R6
15. Wonsey DR, Follettie MT: Loss of the forkhead transcription factor FoxM1 causes centrosome amplification and mitotic catastrophe. Cancer Res 2005, 65:5181-5189
16. Chen PM, Wu TC, Shieh SH, Wu YH, Li MC, Sheu GT, Cheng YW, Chen CY, Lee H: MnSOD promotes tumor invasion via upregulation of FoxM1-MMP2 axis and related with poor survival and relapse in lung adenocarcinomas. Mol Cancer Re 2013, 11:261-271
17. Chu XY, Zhu ZM, Chen LB, Wang JH, Su QS, Yang JR, Lin Y, Xue LJ, Liu XB, Mo XB: FOXM1 expression correlates with tumor invasion and a poor prognosis of colorectal cancer. Acta Histochem 2012, 114:755-762
18. Wang Z, Park HJ, Carr JR, Chen YJ, Zheng Y, Li J, Tyner AL, Costa RH, Bagchi S, Raychaudhuri P: FoxM1 in tumorigenicity of the neuroblastoma cells and renewal of the neural progenitors. Cancer Res 2011, 71:4292-4302
19. He SY, Shen HW, Xu L, Zhao XH, Yuan L, Niu G, You ZS, Yao SZ: FOXM1 promotes tumor cell invasion and correlates with poor prognosis in early-stage cervical cancer. Gynecol Oncol 2012, 127:601-610
20. Raychaudhuri P, Park HJ: FoxM1: a master regulator of tumor metastasis. Cancer Res 2011, 71:4329-4333
21. Wang Y, Wen L, Zhao SH, Ai ZH, Guo JZ, Liu WC: FoxM1 expression is significantly associated with cisplatin-based chemotherapy resistance and poor prognosis in advanced non-small cell lung cancer patients. Lung Cancer 2013, 79:173-179
22. Xia JT, Wang H, Liang LJ, Peng BG, Wu ZF, Chen LZ, Xue L, Li Z, Li W: Overexpression of FOXM1 is associated with poor prognosis and clinicopathologic stage of pancreatic ductal adenocarcinoma. Pancreas 2012, 41:629-635
23. Carr JR, Kiefer MM, Park HJ, Li J, Wang Z, Fontanarosa J, DeWaal D, Kopanja D, Benevolenskaya EV, Guzman G, Raychaudhuri P: FoxM1 regulates mammary luminal cell fate. Cell Rep 2012, 1:715-729
24. Zhang Y, Zhang N, Dai B, Liu M, Sawaya R, Xie K, Huang S: FoxM1B transcriptionally regulates vascular endothelial growth factor expression and promotes the angiogenesis and growth of glioma cells. Cancer Res 2008, 68:8733-8742
25. Herman ME, Katzenellenbogen BS: Response-specific antiestrogen resistance in a newly characterized MCF-7 human breast cancer cell line resulting from long-term exposure to trans-hydroxytamoxifen. J Steroid Biochem Mol Biol 1996, 59:121-134
26. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, Nikolskaya T, Serebryiskaya T, Beroukhim R, Hu M, Halushka MK, Sukumar S, Parker LM, Anderson KS, Harris LN, Garber JE, Richardson AL, Schnitt SJ, Nikolsky Y, Gelman RS, Polyak K: Molecular definition of breast tumor heterogeneity. Cancer Cell 2007, 11:259-273
27. Madak-Erdogan Z, Ventrella R, Petry L, Katzenellenbogen BS: Novel roles for ERK5 and cofilin as critical mediators linking ERα-driven transcription, actin reorganization, and invasiveness in breast cancer. Mol Cancer Res 2014, 12:714-727
28. Madak-Erdogan Z, Charn TH, Jiang Y, Liu ET, Katzenellenbogen JA, Katzenellenbogen BS: Integrative genomics of gene and metabolic regulation by estrogen receptors α and β, and their coregulators. Mol Syst Biol 2013, 9:676
29. Langmead B, Salzberg SL: Fast gapped-read alignment with Bowtie 2. Nat Methods 2012, 9:357-359
30. Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE, Nusbaum C, Myers RM, Brown M, Li W, Liu XS: Model-based analysis of ChIP-Seq (MACS). Genome Biol 2008, 9:R137
31. Hurtado A, Holmes KA, Ross-Innes CS, Schmidt D, Carroll JS: FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat Genet 2011, 43:27-33
32. Ye T, Krebs AR, Choukrallah MA, Keime C, Plewniak F, Davidson I, Tora L: seqMINER: an integrated ChIP-seq data interpretation platform. Nucleic Acids Res 2011, 39:e35
33. Liu T, Ortiz JA, Taing L, Meyer CA, Lee B, Zhang Y, Shin H, Wong SS, Ma J, Lei Y, Pape UJ, Poidinger M, Chen Y, Yeung K, Brown M, Turpaz Y, Liu XS: Cistrome: an integrative platform for transcriptional regulation studies. Genome Biol 2011, 12:R83
34. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA: DAVID: database for annotation, visualization, and integrated discovery. Genome Biol 2003, 4:P3
35. Huang DW, Sherman BT, Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009, 4:44-57
36. McLean CY, Bristor D, Hiller M, Clarke SL, Schaar BT, Lowe CB, Wenger AM, Bejerano G: GREAT improves functional interpretation of cis-regulatory regions. Nat Biotechnol 2010, 28:495-501
37. Galaxy/Cistrome data analysis. [http://cistrome.org/ap/]
38. Frasor J, Chang EC, Komm B, Lin CY, Vega VB, Liu ET, Miller LD, Smeds J, Bergh J, Katzenellenbogen BS: Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. Cancer Res 2006, 66:7334-7340
39. PrimerBank: PCR Primers for Gene Expression Detection and Quantification. [http://pga.mgh.harvard.edu/primerbank/] (accessed 19 September 2014)
40. Hochberg Y, Benjamini Y: More powerful procedures for multiple significance testing. Stat Med 1990, 9:811-818
41. Buffa FM, Camps C, Winchester L, Snell CE, Gee HE, Sheldon H, Taylor M, Harris AL, Ragoussis J: microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. Cancer Res 2011, 71:5635-5645
42. Bergamaschi A, Katzenellenbogen BS: Tamoxifen downregulation of miR-451 increases 14-3-3ζ and promotes breast cancer cell survival and endocrine resistance. Oncogene 2012, 31:39-47
43. Choi YL, Oh E, Park S, Kim Y, Park YH, Song K, Cho EY, Hong YC, Choi JS, Lee JE, Kim JH, Nam SJ, Im YH, Yang JH, Shin YK: Triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival. BMC Cancer 2010, 10:507. A published erratum appears in BMC Cancer 2011, 11:13
44. Kwon MJ, Park S, Choi JY, Oh E, Kim YJ, Park YH, Cho EY, Nam SJ, Im YH, Shin YK, Choi YL: Clinical significance of CD151 overexpression in subtypes of invasive breast cancer. Br J Cancer 2012, 106:923-930
45. Madak-Erdogan Z, Lupien M, Stossi F, Brown M, Katzenellenbogen BS: Genomic collaboration of estrogen receptor α and extracellular signal-regulated kinase 2 in regulating gene and proliferation programs. Mol Cell Biol 2011, 31:226-236
46. Gibert B, Eckel B, Gonin V, Goldschneider D, Fombonne J, Deux B, Mehlen P, Arrigo AP, Clezardin P, Diaz-Latoud C: Targeting heat shock protein 27 (HspB1) interferes with bone metastasis and tumour formation in vivo. Br J Cancer 2012, 107:63-70
47. Sinha S, Singh RK, Bhattacharya N, Mukherjee N, Ghosh S, Alam N, Roy A, Roychoudhury S, Panda CK: Frequent alterations of LOH11CR2A, PIG8 and CHEK1 genes at chromosomal 11q24.1-24.2 region in breast carcinoma: clinical and prognostic implications. Mol Oncol 2011, 5:454-464
48. Thorner AR, Hoadley KA, Parker JS, Winkel S, Millikan RC, Perou CM: In vitro and in vivo analysis of B-Myb in basal-like breast cancer. Oncogene 2009, 28:742-751
49. Kalinichenko VV, Major ML, Wang X, Petrovic V, Kuechle J, Yoder HM, Dennewitz MB, Shin B, Datta A, Raychaudhuri P, Costa RH: Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor. Genes Dev 2004, 18:830-850
50. Ding X-w W, Wu J, Jiang C: ABCG2: a potential marker of stem cells and novel target in stem cell and cancer therapy. Life Sci 2010, 86:631-637
51. Medema JP: Cancer stem cells: the challenges ahead. Nat Cell Biol 2013, 15:338-344
52. Zhang G, Wang Z, Luo W, Jiao H, Wu J, Jiang C: Expression of potential cancer stem cell marker ABCG2 is associated with malignant behaviors of hepatocellular carcinoma. Gastroenterol Res Pract 2013, 2013:782581
53. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, Wicha MS, Dontu G: ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1:555-567
54. Ischenko I, Seeliger H, Schaffer M, Jauch KW, Bruns CJ: Cancer stem cells: how can we target them? Curr Med Chem 2008, 15:3171-3184
55. Visvader JE, Lindeman GJ: Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008, 8:755-768
56. Zhou BB, Zhang H, Damelin M, Geles KG, Grindley JC, Dirks PB: Tumourinitiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 2009, 8:806-823
57. Ahn SG, Lee HM, Lee HW, Lee SA, Lee SR, Leem SH, Jeong J, Chu IS: Prognostic discrimination using a 70-gene signature among patients with estrogen receptor-positive breast cancer and an intermediate 21-gene recurrence score. Int J Mol Sci 2013, 14:23685-23699
58. Kashat M, Azzouz L, Sarkar SH, Kong D, Li Y, Sarkar FH: Inactivation of AR and Notch-1 signaling by miR-34a attenuates prostate cancer aggressiveness. Am J Transl Res 2012, 4:432-442
59. Ma RYM, Tong THK, Leung WY, Yao KM: Raf/MEK/MAPK signaling stimulates the nuclear translocation and transactivating activity of FOXM1. Methods Mol Biol 2010, 647:113-123
60. Zhu J, Zhang Y, Joe GJ, Pompetti R, Emerson SG: NF-Ya activates multiple hematopoietic stem cell (HSC) regulatory genes and promotes HSC self-renewal. Proc Natl Acad Sci U S A 2005, 102:11728-11733
61. Calvanese V, Lara E, Suárez-Alvarez B, Abu Dawud R, Vázquez-Chantada M, Martínez-Chantar ML, Embade N, López-Nieva P, Horrillo A, Hmadcha A, Soria B, Piazzolla D, Herranz D, Serrano M, Mato JM, Andrews PW, López-Larrea C, Esteller M, Fraga MF: Sirtuin 1 regulation of developmental genes during differentiation of stem cells. Proc Natl Acad Sci U S A 2010, 107:13736-13741
62. Tsunoda S, Okumura T, Ito T, Kondo K, Ortiz C, Tanaka E, Watanabe G, Itami A, Sakai Y, Shimada Y: ABCG2 expression is an independent unfavorable prognostic factor in esophageal squamous cell carcinoma. Oncology 2006, 71:251-258
63. Jin Y, Bin ZQ, Qiang H, Liang C, Hua C, Jun D, Dong WA, Qing L: ABCG2 is related with the grade of glioma and resistance to mitoxantone, a chemotherapeutic drug for glioma. J Cancer Res Clin Oncol 2009, 135:1369-1376
64. Selever J, Gu G, Lewis MT, Beyer A, Herynk MH, Covington KR, Tsimelzon A, Dontu G, Provost P, Di Pietro A, Boumendjel A, Albain K, Miele L, Weiss H, Barone I, Ando S, Fuqua SA: Dicer-mediated upregulation of BCRP confers tamoxifen resistance in human breast cancer cells. Clin Cancer Res 2011, 17:6510-6521
65. Hall A: Rho GTPases and the actin cytoskeleton. Science 1998, 279:509-514
66. Etienne-Manneville S, Hall A: Rho GTPases in cell biology. Nature 2002, 420:629-635
67. Carr JR, Park HJ, Wang Z, Kiefer MM, Raychaudhuri P: FoxM1 mediates resistance to herceptin and paclitaxel. Cancer Res 2010, 70:5054-5063
68. Kambach DM, Sodi VL, Lelkes PI, Azizkhan-Clifford J, Reginato MJ: ErbB2, FoxM1 and 14-3-3ζ prime breast cancer cells for invasion in response to ionizing radiation. Oncogene 2013, 33:589-598
69. Gusarova GA, Wang IC, Major ML, Kalinichenko VV, Ackerson T, Petrovic V, Costa RH: A cell-penetrating ARF peptide inhibitor of FoxM1 in mouse hepatocellular carcinoma treatment. J Clin Invest 2007, 117:99-111